



Celgene Corporation
 Investor Relations Department
 86 Morris Avenue
 Summit, NJ 07901
 United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG	
Last Trade:	95.26
Trade Time:	4:15 PM ET Feb 16, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	88.32 - 147.17
Volume	1,673

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 17, 2018 [OTEZLA® \(Apremilast\) Phase III Data Showed Significant Improvements in Patients with Active Behçet's Disease with Oral Ulcers](#)
- Feb 15, 2018 [OTEZLA® \(Apremilast\) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis](#)
- Feb 15, 2018 [Celgene Corporation Elects John Weiland to Its Board of Directors](#)
- Feb 14, 2018 [Celgene Announces Additional \\$5 Billion Share Repurchase Authorization](#)
- Feb 9, 2018 [Celgene Prices \\$4.5 Billion of Senior Unsecured Notes](#)

Upcoming Events [\[View all \]](#)

- Feb 21, 2018 11:30 AM ET [RBC Capital Markets 2018 Global Healthcare Conferenc](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

- Feb 7, 2018 [Annual Report \(10-K\)](#)
- Apr 27, 2017 [Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017 [Quarterly Report \(10-Q\)](#)
- Jul 27, 2017 [Quarterly Report \(10-Q\)](#)
- Apr 27, 2017 [Quarterly Report \(10-Q\)](#)